Petros Pharmaceuticals, Inc. (PTPI) Earnings History
Profitable8 years of earnings data (2018–2025) · Positive TTM net income
Loading earnings history...
Petros Pharmaceuticals, Inc. (PTPI) Earnings Overview
As of June 29, 2026, Petros Pharmaceuticals, Inc. (PTPI) reported trailing twelve-month net income of $3M, reflecting +53.3% year-over-year growth. The company earned $0.07 per diluted share over the past four quarters.
Looking at the long-term picture, PTPI's historical earnings data spans multiple years. The company achieved its highest annual net income of $2M in fiscal 2025, representing a new all-time high.
Petros Pharmaceuticals, Inc. maintains positive profitability with. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including PRGO (-$1.82B net income, -33.5% margin), HIMS (-$13M net income, 5.5% margin), MNKD (-$24M net income, 1.7% margin), PTPI has comparable earnings metrics. Compare PTPI vs PRGO →
PTPI Earnings vs Peers
Earnings metrics vs comparable public companies
PTPI Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $2M | +113.4% | -$5M | $-1.56 | - | - |
| 2024 | -$14M | -75.4% | -$18M | $-3.34 | -280.1% | -345.8% |
| 2023 | -$8M | +59.3% | -$14M | $-6.35 | -140.2% | -233.9% |
| 2022 | -$20M | -123.0% | -$20M | $-9.68 | -334.4% | -332.4% |
| 2021 | -$9M | +56.3% | -$18M | $-8.25 | -115.0% | -231.1% |
| 2020 | -$21M | +36.7% | -$17M | $-38.55 | -215.3% | -180.8% |
| 2019 | -$33M | -0.1% | -$19M | $-132.16 | -208.7% | -124.0% |
| 2018 | -$32M | - | -$8M | $-324.73 | -231.1% | -54.4% |
Download Data
Export PTPI earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
PTPI — Frequently Asked Questions
Quick answers to the most common questions about buying PTPI stock.
What is PTPI earnings per share (EPS)?
PTPI trailing twelve-month (TTM) diluted EPS is $0.07, reflecting +53.3% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2018 to 2025 is available in the table on this page.
What is Petros Pharmaceuticals, Inc.'s net income?
Petros Pharmaceuticals, Inc. (PTPI) trailing twelve-month net income is $3M as of 2025. Earnings grew +53.3% year-over-year.
Is PTPI profitable?
Yes, PTPI is profitable with a TTM net income of $3M and a net profit margin of N/A.
What is PTPI's earnings growth rate?
PTPI compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2018 to 2025.
What are PTPI's profit margins?
Petros Pharmaceuticals, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is +0.1%.
Is PTPI growing earnings?
Yes, PTPI earnings are accelerating — EPS growth of +53.3% exceeds the 5-year CAGR of N/A. TTM net income reached $3M. Earnings momentum is strengthening.
What was PTPI's best earnings year?
Petros Pharmaceuticals, Inc.'s highest annual net income on record is $2M, achieved in fiscal year 2025. Earnings history on this page spans 2018 to 2025 and includes all annual and quarterly figures.
What were PTPI's earnings last quarter?
PTPI's most recent reported quarter was Q1 2026. Net income was $-987036.00 with diluted EPS of $-0.02. For a full breakdown of all quarters, see the quarterly earnings table on this page.